406
Participants
Start Date
July 31, 2015
Primary Completion Date
August 31, 2018
Study Completion Date
August 31, 2018
ALX-0061
Subjects received ALX-0061 150 mg s.c. injections, beginning at Week 0 and q2w thereafter, up to and including Week 102. Subjects from the preceding study ALX0061-C201 also continued their MTX treatment.
Investigator Site 1, Brussels
Investigator Site 2, Brussels
Investigator Site, Ghent
Investigator Site, Liège
Investigator Site, Burgas
Investigator site, Pleven
Investigator Site, Plovdiv
Investigator Site, Rousse
Investigator Site 1, Sofia
Investigator Site 2, Sofia
Investigator Site 1, Tbilisi
Investigator Site 2, Tbilisi
Investigator Site 3, Tbilisi
Investigator Site 4, Tbilisi
Investigator Site 5, Tbilisi
Investigator Site, Hamburg
Investigator Site, Baja
Investigator site, Balatonfüred
Investigator site, Békéscsaba
Investigator Site, Gyula
Investigator Site, Székesfehérvar
Investigator Site, Szikszó
Investigator Site, Szombathely
Investigator Site, Veszprém
Investigator site, Culiacán
Investigator site, León
Investigator site 1, Mexico City
Investigator site 2, Mexico City
Investigator site, Mérida
Investigator site, Monclova
Investigator site 1, Monterrey
Investigator site 2, Monterrey
Investigator Site 1, Chisinau
Investigator site 2, Chisinau
Investigator Site 1, Skopje
Investigator Site 2, Skopje
Investigator Site, Bydgoszcz
Investigator site 1, Elblag
Investigator site 2, Elblag
Investigator Site, Gdynia
Investigator Site, Grodzisk
Investigator Site, Katowice
Investigator Site, Lublin
Investigator Site, Poznan
Investigator Site, Sochaczew
Investigator Site, Torun
Investigator Site 1, Warsaw
Investigator Site 2, Warsaw
Investigator site, Galați
Investigator site, Oradea
Investigator Site 1, Belgrade
Investigator Site 2, Belgrade
Investigator site 3, Belgrade
Investigator Site, Niška Banja
Investigator site, Madrid
Investigator Site, Santander
Investigator Site, Santiago de Compostela
Ablynx, a Sanofi company
INDUSTRY